Duopharma Biotech Bhd 2020 Annual Report with Sustainability Disclosures
Company: Duopharma Biotech Bhd
Sector: Manufacturing
Country: Malaysia
Year: 2020
Type: Annual Report with Sustainability Disclosures
Pages: 190
The report describes Duopharma Biotech's 2020 performance as financially resilient, with revenue of RM569.90 million and record profit before tax of RM76.20 million. It highlights the commencement of commercial production of Lebreta, a breast-cancer drug produced at the Group's HAPI plant. The company also strengthened ESG governance through a Sustainability Management Council and Board Risk Management and Sustainability Committee, while becoming a UN Global Compact Malaysia and Brunei participant. Its 2020 sustainability report was assured by Lloyd's Register.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.